Book contents
- Club Drugs and Novel Psychoactive Substances
- Club Drugs and Novel Psychoactive Substances
- Copyright page
- Contents
- Acknowledgements
- Part I Introduction
- Chapter 1 Introduction
- Chapter 2 What Are Club Drugs and NPS and Why Are They Important?
- Chapter 3 A Brief History of NPS Production and Distribution
- Chapter 4 Classification Framework for Club Drugs and NPS
- Chapter 5 The Clinical Challenge of Club Drugs and NPS
- Part II Stimulant Drugs
- Part III Depressant Drugs
- Part IV Synthetic Cannabinoid Receptor Agonists
- Part V Hallucinogens
- References
- Index
Chapter 1 - Introduction
from Part I - Introduction
Published online by Cambridge University Press: 21 September 2020
- Club Drugs and Novel Psychoactive Substances
- Club Drugs and Novel Psychoactive Substances
- Copyright page
- Contents
- Acknowledgements
- Part I Introduction
- Chapter 1 Introduction
- Chapter 2 What Are Club Drugs and NPS and Why Are They Important?
- Chapter 3 A Brief History of NPS Production and Distribution
- Chapter 4 Classification Framework for Club Drugs and NPS
- Chapter 5 The Clinical Challenge of Club Drugs and NPS
- Part II Stimulant Drugs
- Part III Depressant Drugs
- Part IV Synthetic Cannabinoid Receptor Agonists
- Part V Hallucinogens
- References
- Index
Summary
Over the last decade, the UK, Europe and beyond have seen a dramatic change in the patterns of illicit drug use, particularly in adolescents and those in their twenties for whom heroin and crack cocaine have steadily lost popularity (Figure 1.1). While younger drug users continue to use established drugs such as powder cocaine and MDMA, some are attracted to a range of newly emerging drugs, including so-called club drugs and new psychoactive substances.
- Type
- Chapter
- Information
- Club Drugs and Novel Psychoactive SubstancesThe Clinician's Handbook, pp. 1 - 2Publisher: Cambridge University PressPrint publication year: 2020